Connecticut Eye Consultants PC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$44,360	3
2023	Research	$72,350	3
2022	Research	$19,493	9
2021	Research	$142,890	18
2020	Research	$28,487	6
2019	Research	$45,636	6

Breakdown

Who paid Research payments · program years 2019–2024

Bausch Health US, LLC $167,340 24 payments
EyePoint Pharmaceuticals US, Inc. $101,661 2 payments
Shire North American Group Inc $41,036 5 payments
Oyster Point Pharma, Inc. $21,941 9 payments
AbbVie, Inc. $12,462 3 payments
Takeda Pharmaceuticals U.S.A., Inc. $8,637 1 payment
Boehringer Ingelheim International GmbH $139 1 payment

Studies the money was for Research payments · program years 2019–2024

A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) $101,661 2 payments
A Phase 3, Multi-Center, Randomized, Double- Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (GOBI) $92,200 6 payments
A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects who Completed Trial NVU-003 (SEECASE-2 OLE) $70,540 17 payments
A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 Pvp-Iodine 0.6 and Dexamethasone 0.1 Ophthalmic Suspension in the Treatment of Adenoviral Conjunctivitis $36,658 4 payments
A Phase 2, Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of Oc-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (The Olympia Study) $18,063 7 payments
1698-301-007 Ph3b Study (M21-488) $11,032 1 payment
A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 (Pvp-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension in the Treatment of Adenoviral Conjunctivitis $8,637 1 payment
Retrospective Assessment of Latanoprostene Bunod Ophthalmic Solution 0.024 in Patients Newly Diagnosed with Open Angle Glaucoma or Ocular Hypertension $4,600 1 payment
A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 Pvp-Iodine 0.6 and Dexamethasone 0.1 Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis $4,378 1 payment
A Phase 2 Multicenter Randomized Controlled Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of Oc-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (The Olympia Study) $3,877 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.